Profits drive the rising prices of MS drugs in the US, finds a new study based on interviews with four pharmaceutical executives published in Neurology. In Europe, the price of a drug is typically highest when it launches and declines over time. The opposite appears to be the case in the US.

Profits drive the rising prices of MS drugs in the US, finds a new study based on interviews with four pharmaceutical executives published in Neurology. In Europe, the price of a drug is typically highest when it launches and declines over time. The opposite appears to be the case in the US.: https://ift.tt/34tmAXH Read more... https://ift.tt/34tf8Mr